Pergolide

Medical uses

Pergolide is no longer available for use by humans in the United States, however, it is still used in various other countries, where it is used to treat various conditions including Parkinson's disease, hyperprolactinemia, and restless leg syndrome.

Pergolide is available for veterinary use. Under the trade name Prascend, manufactured by Boehringer Ingelheim, it is commonly used for the treatment of pituitary hyperplasia at the pars intermedia or Equine Cushing's Syndrome (ECS) in horses.

Pharmacology

Pharmacodynamics

Pergolide acts as an agonist of dopamine D2 and D1 and serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT2C receptors. It may possess agonist activity at other dopamine receptor subtypes as well, similar to cabergoline. Although pergolide is more potent as an agonist of the D2 receptor, it has high D1 receptor affinity and is one of the most potent D1 receptor agonists of the dopamine receptor agonists that are clinically available. The agonist activity of pergolide at the D1 receptor somewhat alters its clinical and side effect profile in the treatment of Parkinson's disease. Pergolide has been said to be hallucinogenic due to activation of 5-HT2A receptors. However, other sources have stated that the drug is non-hallucinogenic. It has been associated with cardiac valvulopathy due to activation of 5-HT2B receptors.

Side effects

The drug is in decreasing use, as it was reported in 2003 to be associated with a form of heart disease called cardiac fibrosis. In 2007, the United States Food and Drug Administration announced a voluntary withdrawal of the drug by manufacturers due to the possibility of heart valve damage. Pergolide is not currently available in the United States for human use. This problem is thought to be due to pergolide's action at the 5-HT2B serotonin receptors of cardiac myocytes, causing proliferative valve disease by the same mechanism as ergotamine, methysergide, fenfluramine, and other serotonin 5-HT2B agonists, including serotonin itself when elevated in the blood in carcinoid syndrome. Pergolide can rarely cause Raynaud's phenomenon. Among similar antiparkinsonian drugs, cabergoline, but not lisuride, exhibit this same type of serotonin receptor binding. In January 2007, cabergoline (Dostinex) was also reported to be associated with valvular proliferation heart damage. In March 2007, pergolide was withdrawn from the U.S. market for human use due to serious valvular damage that was shown in two independent studies.

Pergolide has also been shown to impair associative learning.

Addictive behaviors

At least one British pergolide user has attracted some media attention with claims that it has caused him to develop a gambling addiction. In June 2010, it was reported that more than 100 Australian users of the drug are suing the manufacturer over both gambling and sex addiction problems they claim are the result of the drug's side effects.

Society and culture

Brand names

Brand names of pergolide include Permax and Prascend (veterinary), among others.

Research

Pergolide has been studied in the treatment of social anxiety disorder in one small study but was found to be ineffective.

References

References

1. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. "6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds".
3. (2006). "Analogue-based Drug Discovery". John Wiley & Sons.
4. "Pergolide (marketed as Permax)". FDA Public Health Advisory.
5. "Pergolide for Veterinary Use".
6. "Prascend for Horses". Valley Vet Supply.
7. (May 2010). "Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum". Neuropsychopharmacology.
8. (February 2010). "Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review". Headache.
9. (October 2008). "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells". European Journal of Pharmacology.
10. (January 2024). "Psychedelics: preclinical insights provide directions for future research". Neuropsychopharmacology.
11. (2014). "Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy". Journal of Pharmacological and Toxicological Methods.
12. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics.
13. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics.
14. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics.
15. "PDSP Database - UNC".
16. (2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics.
17. (August 2004). "Cardiac valvulopathy with pergolide". Aust Adv Drug React Bull.
18. "Pergolide (marketed as Permax)". Public Health Advisory.
19. [""Pergolide and Cabergoline But not Lisuride Exhibit Agonist Efficacy at Serotonin 5-HT_2B Receptors"."](https://userpage.fu-berlin.de/~hpertz/Presentation001.pdf }} {{small).
20. (January 2007). "Dopamine agonists and the risk of cardiac-valve regurgitation". The New England Journal of Medicine.
21. (March 29, 2007). "MedWatch - 2007 Safety Information Alerts. Permax (pergolide) and generic equivalents". U.S. [[Food and Drug Administration]].
22. (November 2006). "Tonic dopaminergic stimulation impairs associative learning in healthy subjects". Neuropsychopharmacology.
23. (24 January 2008). "Drug 'caused' gambling addiction". BBC TV.
24. (5 February 2008). "Parkinson's Gambler". ITV.com.
25. (4 June 2010). "Parkinson's treatment linked to sex, gambling". The Age.
26. "Pergolide". Drugs.com.
27. (October 2000). "Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI". Expert Opinion on Investigational Drugs.
28. (2000). "Treatment of social phobia with the dopamine agonist pergolide". Depression and Anxiety.